First-Line Therapy for Newly Diagnosed DLBCL
R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) given every 21 days remains the standard first-line therapy for most adult patients with newly diagnosed diffuse large B-cell lymphoma without contraindications. 1
Treatment Stratification by Age and Risk
The optimal regimen depends critically on age and age-adjusted International Prognostic Index (aaIPI) score:
Patients Aged 60-80 Years
- Eight cycles of R-CHOP-21 (every 21 days) with eight doses of rituximab is the established standard 1
- This represents Level I, Grade A evidence
- R-CHOP-14 (every 14 days) showed no survival advantage over R-CHOP-21 1
- If using R-CHOP-14, six cycles with eight rituximab doses are sufficient 1
- Consolidation radiotherapy provides no benefit in localized disease 1
Young Low-Risk Patients (Age <60, aaIPI ≤1)
- Six to eight cycles of R-CHOP-21 with six to eight doses of rituximab 2, 3
- This is Level I, Grade A evidence
- For patients with bulky disease, consider R-CHOP-21 × 6 cycles plus radiotherapy to bulky sites 1
- Alternative for low-intermediate risk (aaIPI=1): R-ACVBP (rituximab, doxorubicin, vindesine, cyclophosphamide, bleomycin, prednisolone every 2 weeks with sequential consolidation) showed improved survival compared to eight cycles of R-CHOP, though radiotherapy was omitted 1
Young High-Risk Patients (Age <60, aaIPI ≥2)
- No definitive standard exists—clinical trial enrollment is strongly preferred 1, 3
- Most commonly applied: Six to eight cycles of R-CHOP-21 with eight rituximab doses 1
- Level III, Grade B evidence
- Dose-dense R-CHOP-14 has not demonstrated survival benefit 1
Patients Aged >80 Years
- R-CHOP can be used until age 80 in healthy patients 1
- For patients >80 years: R-miniCHOP (attenuated chemotherapy with rituximab) can induce complete remission and long survival 1
- Consider doxorubicin substitution with etoposide or liposomal doxorubicin, or omit doxorubicin entirely in patients with cardiac dysfunction 1
- Comprehensive geriatric assessment is mandatory to guide treatment selection 1
Critical Management Principles
Tumor Lysis Syndrome Prevention
In patients with high tumor burden, administer prednisone 100 mg orally for several days as "prephase" treatment before starting chemotherapy 1
Dose Intensity Maintenance
- Avoid dose reductions due to hematological toxicity 1, 2, 1
- Febrile neutropenia justifies prophylactic hematopoietic growth factors in all patients treated with curative intent and all elderly patients 1
CNS Prophylaxis
Patients at high risk for CNS relapse require prophylaxis:
- High-intermediate and high-risk IPI (especially >1 extranodal site or elevated LDH) 1
- Testicular lymphoma mandates CNS prophylaxis 1
- Intrathecal methotrexate is probably suboptimal; intravenous high-dose methotrexate with efficient disease control is preferred 1
- Consider prophylaxis for paranasal sinus, upper neck, or bone marrow involvement (though not definitively established) 1
Common Pitfalls to Avoid
Do not use R-CHOP-14 expecting superior outcomes—it provides no survival advantage over R-CHOP-21 1
Do not routinely add consolidation radiotherapy in patients with localized disease who achieve complete remission—it provides no proven benefit in the rituximab era 1
Do not reduce chemotherapy doses for hematological toxicity—use growth factor support instead to maintain dose intensity 1
Do not omit CNS prophylaxis in high-risk patients, particularly those with testicular involvement 1
Emerging Evidence (Context Only)
While R-CHOP remains standard, recent data suggest polatuzumab vedotin-R-CHP may offer superior progression-free survival in patients with IPI ≥2 4, 5. However, the guidelines provided do not include this as a formal recommendation, and R-CHOP remains the established standard based on the strongest guideline evidence 1.